Technical Analysis for 0HFR - Anavex Life Sciences Corp.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 3.45 | 0.00% | 0.00 |
Earnings due: May 7
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Downtrend | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% |
| Alert | Time |
|---|---|
| Down 2% | about 21 hours ago |
| Down 1% | about 21 hours ago |
| Possible Inside Day | about 21 hours ago |
| Possible NR7 | about 21 hours ago |
| Fell Below Previous Day's Low | 2 days ago |
Free Daily (Stock) Chart Reading
Anavex Life Sciences Corp. Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Classification
Keywords: Health Pain Diseases Pharmaceutical Industry Drug Discovery Clinical Trial Alzheimer's Disease Multiple Sclerosis Parkinson's Disease Stroke Clinical Research Alzheimer's Diseases Design Of Experiments Epilepsy Food And Drug Administration Pancreatic Cancer Parkinson Depression Stage Biopharmaceutical
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.446 |
| 52 Week Low | 3.3 |
| Average Volume | 5,931 |
| 200-Day Moving Average | 6.55 |
| 50-Day Moving Average | 4.76 |
| 20-Day Moving Average | 4.15 |
| 10-Day Moving Average | 3.79 |
| Average True Range | 0.22 |
| RSI (14) | 27.01 |
| ADX | 25.95 |
| +DI | 16.44 |
| -DI | 43.70 |
| Chandelier Exit (Long, 3 ATRs) | 4.52 |
| Chandelier Exit (Short, 3 ATRs) | 3.96 |
| Upper Bollinger Bands | 5.03 |
| Lower Bollinger Band | 3.27 |
| Percent B (%b) | 0.1 |
| BandWidth | 42.47 |
| MACD Line | -0.39 |
| MACD Signal Line | -0.34 |
| MACD Histogram | -0.0512 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.56 | ||||
| Resistance 3 (R3) | 3.54 | 3.50 | 3.54 | ||
| Resistance 2 (R2) | 3.50 | 3.47 | 3.50 | 3.53 | |
| Resistance 1 (R1) | 3.47 | 3.45 | 3.49 | 3.49 | 3.53 |
| Pivot Point | 3.43 | 3.43 | 3.43 | 3.43 | 3.43 |
| Support 1 (S1) | 3.40 | 3.40 | 3.42 | 3.42 | 3.37 |
| Support 2 (S2) | 3.36 | 3.38 | 3.36 | 3.37 | |
| Support 3 (S3) | 3.33 | 3.36 | 3.36 | ||
| Support 4 (S4) | 3.35 |
